At Ipsen we believe in advancing science with a purpose. With our unique size and specialized expertise, we make a difference for patients around the world living with high unmet medical needs.
Across oncology, rare diseases and neurological conditions, we bring innovation where patients have the fewest options.
Our purpose in oncology is to push the boundaries of innovation, following the science to advance next-generation modalities for difficult-to-treat cancers, transforming treatment for patients with high unmet medical needs.
Our purpose in rare diseases is to apply cutting-edge science to develop targeted therapies for complex conditions such as rare bone, endocrine, and liver diseases, where treatment options remain limited.
Our purpose in neurological conditions is to harness advanced neuroscience and innovative modalities, including neurotoxins and RNA-targeting therapies, to develop transformative treatments for patients with debilitating and underserved disorders.
Ipsen’s global team of over 5,000 people across 40 countries, is dedicated to advancing transformative science for some of the most challenging medical conditions. Our unique size and expertise enable us to identify and accelerate groundbreaking science with a purpose, bringing innovations to patients so that people around the world can benefit. From molecule to patient, our end-to-end approach is rooted in data-driven science, enabling us to unlock potential long before it reaches the clinic. Combining our pharmaceutical development expertise with our clinical knowhow and deep regulatory capabilities, we design the most effective clinical and registry path to demonstrate and bring the value of a potential new therapy.
We accelerate innovation by combining our internal expertise with external partnerships to identify and advance first- and best-in-class programs with the potential to transform lives.
Our strength lies in our commitment—blending science with purpose.
Assessing the benefits of early intervention in post-stroke care
With over 12 million people a year experiencing a stroke globally and over 100 million living with the effects and consequences of stroke, the burden of stroke is high and set to increase.
Neuro Connections
Watch our three-part vodcast series, Neuro Connections, developed in collaboration with the World Stroke Organization, where we discuss current post-stroke care challenges and potential solutions with global specialists, advocates and healthcare professionals.
Addressing the cost of inaction in post-stroke care
At Ipsen, we are invested in helping people who are navigating the challenges of living with debilitating neurological conditions, including those living with the consequences of a stroke.
The Ixcellence Network®: celebrating 10 years of progress in improving the standard of care for patients living with debilitating neurological disorders
Continuing medical education is vital to maintaining the quality of clinical practice, which in turn can improve patient outcomes. As a pioneer in botulinum neurotoxin type A (BoNT-A) treatment, Ipsen has worked with a scientific steering committee of international experts…
Assessing the benefits of early intervention in post-stroke care
With over 12 million people a year experiencing a stroke globally and over 100 million living with the effects and consequences of stroke, the burden of stroke is high and set to increase.
Neuro Connections
Watch our three-part vodcast series, Neuro Connections, developed in collaboration with the World Stroke Organization, where we discuss current post-stroke care challenges and potential solutions with global specialists, advocates and healthcare professionals.
Addressing the cost of inaction in post-stroke care
At Ipsen, we are invested in helping people who are navigating the challenges of living with debilitating neurological conditions, including those living with the consequences of a stroke.
The Ixcellence Network®: celebrating 10 years of progress in improving the standard of care for patients living with debilitating neurological disorders
Continuing medical education is vital to maintaining the quality of clinical practice, which in turn can improve patient outcomes. As a pioneer in botulinum neurotoxin type A (BoNT-A) treatment, Ipsen has worked with a scientific steering committee of international experts…
OUR PARTNERSHIPS
At Ipsen, we believe that partnerships create possibilities. We seek to build partnerships that boost our capacity to improve or extend the lives of people living with cancer, rare diseases and neurological conditions.
Learn more
CLINICAL TRIALS
Ipsen conducts first-in-the-world clinical trials to take science forward and bring innovative, new options to patients. Our global network of healthcare professionals, together with volunteers and patients, helps us test medicines and ensure their effectiveness and safety in clinical trials before new treatments can be approved and made widely available.
Learn more